News Releases

 
Intrasense admitted to NYSE Alternext
Paris, 22 February 2012 – NYSE Euronext today announced the listing of Intrasense, a key European publisher of software used in radiology diagnostics, on NYSE Alternext in Paris.

Founded in 2004, with offices in Montpellier, Paris and Shanghai, Intrasense designs, develops and markets Myrian®, an advanced software suite used by experts to analyse medical images in three dimensions. This pioneering system is an invaluable aid to radiologists, surgeons and clinicians, who use it to ensure accurate diagnosis, plan therapy, and track certain pathologies, notably tumors. Intrasense has 44 employees, all bilingual and with a strong international focus, who work in either Research & Development or in marketing.

Intrasense (ticker code: ALINS) was listed through the admission to trading of 2,152,020 existing shares and 571,561 shares (of which 523,941 new shares) issued under a Global Offering[1], including full exercise of the extension clause and the partial exercise of the Over-allotment Option. The Global Offering raised a total of €4.2 million.

The admission and issue price of Intrasense shares was set at €7.40. Market capitalisation stood at around €21 million on the day of listing. 

“We are delighted with Intrasense’s successful listing on NYSE Alternext this year’s first on our market with lighter regulatory requirements that is tailor-made  for SMEs. Intrasense is also the third company in the health sector to join us in just a few days” said Marc Lefèvre, Head of European Coverage at NYSE Euronext. “Listing is a milestone that will raise the company’s profile with investors and generate the financing it needs to step up its growth and continue building an efficient international distribution network,” he noted. 

Intrasense Chairman Stéphane Chemouny and CEO Patrick Mayette added: “We are very pleased to be the first listing of the year on NYSE Alternext, joining the group of high-growth companies that have turned to the market to finance their development. We would like to take this opportunity to thank our employees, whose dedication adds value to Intrasense technology every day, as well as all the shareholders who have enabled us to list today and gain access to the resources we need to deploy our international strategy. As you now know, Intrasense is a core player in France’s fast-moving medical imaging industry. Our aim is to shape the industry as it advances.

In six years,
 €2.6 billion has been raised on NYSE Alternext, half through secondary issues, by companies from countries including Belgium, Canada, China, France, Italy, Luxembourg, the Netherlands, Spain, the UK and the US. Their market capitalization totals €5.9 billion. There are currently 180 companies listed on NYSE Alternext.

--------------------------------
[1] The Global Offering was made up of an Open Price Public Offering and a Global Placement with institutional investors in France and other countries.

Contacts:

NYSE Euronext                                                                                                
Caroline Tourrier: +33 (0)1 49 27 10 82 – ctourrier@nyx.com

Intrasense
NewCap.
Alexandra Schiltz / Pierre Laurent: +33 (0)1 44 71 94 94 – intrasense@newcap.fr                                                          

About NYSE Euronext
NYSE Euronext (NYX) is a leading global operator of financial markets and provider of innovative trading technologies. The company's exchanges in Europe and the United States trade equities, futures, options, fixed-income and exchange-traded products. With approximately 8,000 listed issues (excluding European Structured Products), NYSE Euronext's equities markets — the New York Stock Exchange, NYSE Euronext, NYSE Amex, NYSE Alternext and NYSE Arca — represent one-third of the worlds equities trading, the most liquidity of any global exchange group. NYSE Euronext also operates NYSE Liffe, one of the leading European derivatives businesses and the world's second-largest derivatives business by value of trading. The company offers comprehensive commercial technology, connectivity and market data products and services through NYSE Technologies. NYSE Euronext is in the S&P 500 index, and is the only exchange operator in the Fortune 500. For more information, please visit: www.nyx.com.

About Intrasense
Founded in 2004 and based on innovative technology for detecting tissues with scanner imaging, Intrasense designs, develops and markets Myrian®, a suite of advanced medical software that allows specialists to review and analyse multimodal medical images (IRM, scanner, TEP, X-ray and more). Developed with top partners from academia, Myrian® combines and uses all types of medical imaging to extract information essential to patient diagnostics, swift evaluation of the effectiveness of therapies, and, by extension, the assessment of drugs undergoing trials for cancer treatments. The software is now used at 300 client sites around the world. Myrian® is a “medical device” certified for use in over 40 countries, including the United States (FDA), Europe (CE) and Asia. Intrasense has 44 employees, 20 working in Research & Development. The company has been recognized as an “innovative business” by Oseo (France) and has invested over €8 million in R&D since its inception. For more information visit : www.intrasense.fr.

 



[1]The Global Offering was made up of an Open Price Public Offering and a Global Placement with institutional investors in France and other countries.